Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia

Nature Reviews Clinical Oncology

Volumn 9, Issue 6, 2012, Pages 310-311

  Ravandi, Farhad ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CLADRIBINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG TOLERABILITY; EVENT FREE SURVIVAL; HUMAN; LEUKEMIA REMISSION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENCE FREE SURVIVAL; REVIEW;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS;

EID: 84861720251     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.83     Document Type: Review

References (10)

1. Kern, W. & Estey, E. H. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 107, 116-124 (2006). (Pubitemid 43939038)
2. Willemze, R et al. High dose (HD-AraC) vs. standard dose cytosine arabinoside (SD-AraC) during induction and IL 2 vs. observation after consolidation/autologous stem cell transplantation in patients with acute myelogenous leukemia (AML): Final report of the AML 12 trial of EORTC and GIMEMA Leukemia groups on the value of high dose AraC [abstract]. Blood 118, a257 (2011).
3. Löwenberg, B. et al. Cytarabine dose for acute myeloid leukemia. N. Engl. J. Med. 364, 1027-1036 (2011).
4. Bloomfield, C. D. et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 58, 4173-4179 (1998). (Pubitemid 28440576)
5. Fernandez, H. F. et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361, 1249-1259 (2009).
6. Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA 0701): a randomised, open-label, phase 3 study. Lancet http://dx.doi.org/10.1016/S0140-6736(12)60485- 1.
7. Petersdorf, S. et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood 114, a790 (2009).
8. Burnett, A. K. et al. Identification of patients with acute myeloblastic leukaemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J. Clin. Oncol. 29, 369-377 (2011).
9. Delaunay, J. et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study [abstract]. Blood 118, a79 (2011).
10. Burnett, A. K. et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UK NCRI AML16 randomized trial [abstract]. Blood 118, a582 (2011).